ENTX
HEALTHCAREEntera Bio Ltd
AI Insight
What's Moving ENTX Today?
No stock-specific AI insight has been generated for ENTX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.91$3.22
$1.55
Fundamentals
Market Cap$73M
P/E Ratio—
EPS$-0.26
Dividend Yield—
Dividend / Share—
ROE-82.3%
Profit Margin—
Debt / Equity—
Trading
Volume1.8M
Avg Volume (10D)—
Shares Outstanding49.3M
ENTX News
25 articles- Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with OsteoporosisGlobeNewswire·Jun 22, 2026
- ENTX Stock On Track For Best Day In Over 5 Years — What’s Driving The Rally?Stocktwits·Jun 22, 2026
- Entera Bio Ltd (ENTX) Dividends & Stock Splits: Historical Payouts and Event TimelineTradingKey·Jun 18, 2026
- Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026Yahoo Finance·Jun 16, 2026
- ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)Yahoo Finance·Jun 15, 2026
- Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for PresentationYahoo Finance·May 28, 2026
- Press Release: Entera Announces First Quarter 2026 Financial Results and Updates Across Its Oral Peptide ProgramsMoomoo·May 9, 2026
- Entera Bio (ENTX) widens Q1 loss as R&D doubles and cash runway nears Q1 2027Stock Titan·May 9, 2026
- Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide ProgramsYahoo Finance·May 8, 2026
- Entera Bio (ENTX) Upgraded to Buy: Here's What You Should KnowYahoo Finance·Apr 29, 2026
- Entera Bio Touts EB613 Oral Anabolic Tablet as Osteoporosis Care Gap Persists, Phase III NearMarketbeat·Apr 24, 2026
- BriefCast Publishes Transcript: Entera Bio's Osteoporosis KOL Roundtable on EB613 - Oral Anabolic Tablet OpportunityYahoo Finance·Apr 20, 2026
- Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613Yahoo Finance·Apr 14, 2026
- Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total ProceedsYahoo Finance·Apr 2, 2026
- Stock Market Today: S&P 500, Dow, Nasdaq Futures Gain As Trump Calls Iran's New Leaders 'Very Reasonable'— PLTR, RZLV, ENTX In Focus (UPDATED)Benzinga·Mar 30, 2026
- Stock Market Today: S&P 500, Dow Futures Gain As Trump Calls Iran's New Leaders 'Very Reasonable'—Palantir, Rezolve AI, Entera Bio In FocusBenzinga·Mar 30, 2026
- Entera Bio Announces Full Year 2025 Financial Results and Provides Business UpdatesYahoo Finance·Mar 27, 2026
- Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with OsteoporosisYahoo Finance·Mar 4, 2026
- Matricelf Ltd. (TASE: MTLF) Appoints Ron Mayron as Chairman of the BoardYahoo Finance·Feb 27, 2026
- Entera Bio to Participate in the Leerink Partners 2026 Global Healthcare ConferenceYahoo Finance·Feb 26, 2026
- Opko Health Inc. (OPK) Builds Value Through Partnerships and InnovationYahoo Finance·Feb 18, 2026
- Entera Bio Announces Open Market Purchases of Company Stock by Board MembersYahoo Finance·Feb 11, 2026
- Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key MilestonesYahoo Finance·Feb 9, 2026
- Opko Health (OPK) Expands Entera Partnership for Drug Co-DevelopmentYahoo Finance·Feb 6, 2026
- OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with HypoparathyroidismYahoo Finance·Feb 4, 2026
All 25 articles loaded
Price Data
Open$1.36
Previous Close$1.48
Day High$1.60
Day Low$1.28
52 Week High$3.22
52 Week Low$0.91
52-Week Range
$0.91$3.22
$1.55
Fundamentals
Market Cap$73M
P/E Ratio—
EPS$-0.26
Dividend Yield—
Dividend / Share—
ROE-82.3%
Profit Margin—
Debt / Equity—
Trading
Volume1.8M
Avg Volume (10D)—
Shares Outstanding49.3M
About Entera Bio Ltd
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally administered large molecule therapies for unmet medical needs. The company is headquartered in Jerusalem, Israel.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—